Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
作者信息
Chao Jennifer, Bansilal Sameer
机构信息
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Glob Heart. 2016 Dec;11(4):469-472. doi: 10.1016/j.gheart.2016.10.020.
PMID:27938845
Abstract
摘要
相似文献
1
Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Glob Heart. 2016 Dec;11(4):469-472. doi: 10.1016/j.gheart.2016.10.020.
2
[The polypill: optimal strategy for reduction of cardiovascular disease].
Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740.
3
The Polypill in the prevention of cardiovascular disease.
Prev Med. 2011 Jan;52(1):16-7. doi: 10.1016/j.ypmed.2010.11.015. Epub 2010 Dec 2.
4
[The polypill: not an effective strategy for reduction of cardiovascular disease].
Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1741.
5
A single pill for prevention?
Harv Heart Lett. 2009 Jul;19(11):6.
6
Combination therapy to prevent cardiovascular disease: slow progress.
JAMA. 2013 Apr 17;309(15):1595-6. doi: 10.1001/jama.2013.3180.
7
Improving cardiovascular protection: focus on a cardiovascular polypill.
Future Cardiol. 2016 Mar;12(2):181-96. doi: 10.2217/fca.15.80. Epub 2015 Dec 10.
8
The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
Eur J Prev Cardiol. 2020 Mar;27(4):437-440. doi: 10.1177/2047487319872660. Epub 2019 Aug 25.
9
Polypill in cardiovascular disease: has it's time come?
Indian Heart J. 2009 Jul-Aug;61(4):322-7.
10
Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.
Zotero 插件